Muddathir Abdel Rahim Mahmoud, Hamid Tarig A M, Elamin Elwaleed M, Khabour Omar F
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Taibah University, Medina, Kingdom of Saudi Arabia.
Department of Hematology and Blood Transfusion, Faculty of Medical Laboratory Science, Alzaeim Alazhari University, Khartoum, Sudan.
Int J Health Sci (Qassim). 2021 Mar-Apr;15(2):21-25.
Acute myeloid leukemia (AML) is a common malignant disorder of hematopoietic progenitor cells that caused by chromosomal translocation and the formation of fusion oncogenes. This study determined the frequencies of fusion genes in Sudanese patients with AML and their clinical impacts.
This study was conducted at Alzaeim Alazhari University, Khartoum, Sudan. A total of 97 patients with AML were recruited in the study from different clinics in Khartoum state. Quantitative real-time polymerase chain reaction was used to determine types of fusion genes.
The highest frequency of genetic defects was observed for fusion gene (57.6%) followed by (35.1%) and (7.2%). No significant differences in blast cells, hemoglobin, total white blood cells, and platelets were found between different gene fusion groups ( > 0.05). In addition, no differences in the frequency of splenomegaly, hepatomegaly and lymphadenopathy were observed between different gene fusion groups ( > 0.05). With respect to French-American-British (FAB) classification, the M2 and M3 were significantly higher in patients with fusion (86%, < 0.01) whereas M4 and M5 were higher in patients with fusion (76.5%, < 0.01).
The study concluded that and fusion genes were predominant in AML Sudanese patients. None of the examined clinical parameters were different between different fusion genes except for FAB stages.
急性髓系白血病（AML）是一种常见的造血祖细胞恶性疾病，由染色体易位和融合癌基因的形成引起。本研究确定了苏丹AML患者中融合基因的频率及其临床影响。
本研究在苏丹喀土穆的阿尔扎伊姆·阿拉扎里大学进行。从喀土穆州的不同诊所招募了97例AML患者。采用定量实时聚合酶链反应来确定融合基因的类型。
观察到融合基因的遗传缺陷频率最高（57.6%），其次是（35.1%）和（7.2%）。不同基因融合组之间在原始细胞、血红蛋白、总白细胞和血小板方面未发现显著差异（>0.05）。此外，不同基因融合组之间在脾肿大、肝肿大和淋巴结病的频率上也未观察到差异（>0.05）。关于法美英（FAB）分类，融合患者中M2和M3显著更高（86%，<0.01），而融合患者中M4和M5更高（76.5%，<0.01）。
该研究得出结论，融合基因和在苏丹AML患者中占主导地位。除了FAB分期外，不同融合基因之间的所有检测临床参数均无差异。
